Purchase this article with an account.
Y. Yamada, S. Sugita, T. Kawaguchi, M. Miyanaga, M. Mochizuki; The Safety of Infliximab in Behcet’s Disease With Refractory Uveoretinitis. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5265.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess the safety of infliximab treatment in patients with Behcet’s disease with refractory uveoretinitis.
Clinical charts of 36 consecutive patients with Behcet’s disease treated with infliximab at our hospital were retrospectively reviewed. Side effects during the whole follow up period under infliximab (1-49 months: average 18months) were recorded.
Side effects were observed in 21 patients (58%): dermatological events (9 patients; infusion reaction not included), infusion reaction (8), enteritis (3), leucopenia (2), tuberculosis (1), bacterial pneumonia (1), cellulitis (1), myalgia (1), transaminases increase (1). Serious side effects were observed in 2 patients (6%), which included tuberculosis (n=1) and bacterial pneumonia (n=1). Of the 8 patients who caused infusion reaction, 6 patients had mild-severe acute episodes of uveitis. Eight patients (22%) discontinued the therapy due to infusion reaction in two, move to distance cities in two, and one each due to tuberculosis, bacterial pneumonia, leucopenia, increase of transaminases values.
The majority adverse events in patients treated with infliximab were mild. However, a much longer observation is necessary to ensure its safety, especially infections.
This PDF is available to Subscribers Only